Vaishali Pharma P/E Ratio
Current P/E Ratio
24.68
Moderate Valuation
High - Growth expectations or overvalued
Vaishali Pharma P/E ratio. Vaishali Pharma (VAISHALI) P/E ratio is 24.68 (Moderate), EPS (TTM) ₹0.31, current price ₹8.17 on NSE — High - Growth expectations or overvalued. Examine VAISHALI earnings report for recent quarterly revenue, profit and EPS trends.
Current Valuation Metrics
P/E Ratio
24.68
Current Price
₹8.17
EPS (TTM)
₹0.31
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.35
Sector Median
32.5
Sector Rank
#11 of 199
Sector Percentile
5.5%
Earnings Breakdown (TTM)
TTM EPS
₹0.34
Mar 2026
₹0.03
Jun 2026
₹0.12
VAISHALI P/E Ratio — Valuation Signal & Historical Context
Vaishali Pharma P/E 24.68 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see VAISHALI screener.
- Trading at discount to sector average PE of 56.35
VAISHALI vs Healthcare Peers — P/E Ratio Comparison
Vaishali Pharma P/E 24.68 vs Healthcare average 56.35, median 32.5 — range 2.04–740.29.
Sector Average
56.35
Sector Median
32.5
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |